Volume 6, Issue 4, December 2018, Page: 95-98
The Clinical and Dynamic Characteristics of Acute Psychosis Following the Use Synthetic Cannabinoids
Kekelidze Zurab Ilich, V. Serbsky Federal Medical Research Center of Psychiatry and Addiction, Ministry of Health, Moscow, Russian Federation
Klimenko Tatiana Valentinovna, V. Serbsky Federal Medical Research Center of Psychiatry and Addiction, Ministry of Health, Moscow, Russian Federation; Department of Criminal Procedure and Forensic Science, The All-Russian State University of Justice, Ministry of Justice, Moscow, Russian Federation
Kozlov Alexandr Alexandrovich, V. Serbsky Federal Medical Research Center of Psychiatry and Addiction, Ministry of Health, Moscow, Russian Federation
Shakhova Svetlana Michailovna, V. Serbsky Federal Medical Research Center of Psychiatry and Addiction, Ministry of Health, Moscow, Russian Federation
Received: Aug. 16, 2018;       Accepted: Sep. 7, 2018;       Published: Oct. 23, 2018
DOI: 10.11648/j.ajpn.20180604.11      View  164      Downloads  8
Abstract
The article presents the results of research into the clinical and dynamic characteristics of psychosis following the use of synthetic cannabinoids (SC). The aim of the study is a clinical-dynamic analysis of 348 psychotic conditions following the use of synthetic cannabinoids involved 173 patients. The results of the study are: we describe the stages of psychosis development and psychosis delirious, delirious-oneiroid and amentia-like clinical variants; we demonstrated that the pathokinetic patterns of psychosis following SC use are determined by a complex of clinical, biological and socio-psychological factors; we found that the severity of clinical variants of the psychosis and consciousness disorders positively correlated with psychopathological conditions accompanied by more and more severe disorders of psychic activity (affective disorders – illusions and pareidolias – hallucinations – delusions – psychic automatism – ‘motor disorders) with simultaneous gradual depletion of psychosis psychopathologic picture resulting from the narrowing spectrum of psychopathological symptoms.
Keywords
New Psychoactive Substances, Synthetic Cannabinoids, Spice, Psychosis
To cite this article
Kekelidze Zurab Ilich, Klimenko Tatiana Valentinovna, Kozlov Alexandr Alexandrovich, Shakhova Svetlana Michailovna, The Clinical and Dynamic Characteristics of Acute Psychosis Following the Use Synthetic Cannabinoids, American Journal of Psychiatry and Neuroscience. Vol. 6, No. 4, 2018, pp. 95-98. doi: 10.11648/j.ajpn.20180604.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Savchuk S. A. Obnaruzheniesinteticheskikhkannabimimetikov, narkoticheskikh, psikhoaktivnykhveshchestv i ikhmetabolitov v moche, volosakh i nogtyakhmetodamizhidkostnoikhromatografii s mass-spektrometricheskimdetektirovaniem. Informatsionnoepis'mo. «Narkologiya» 8/2014, str. 42-52 (In Russ.).
[2]
Vsemirnyidoklad o narkotikakh, 2016 Available at: http://www.unodc.org/doc/wdr2016/WDR_2016_ExSum_russian.pdf AccessedMay10, 2017.
[3]
National Institute on Drug Abuse. DrugFacts: K2/Spice («SyntheticMarijuana»). Available at: https://www.drugabuse.gov/drugs-abuse/synthetic-cannabinoids-k2spice AccessedMay10, 2017.
[4]
European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids and «Spice» profile. Available at: http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids AccessedMay10, 2017.
[5]
Bokhan N. A., Selivanov G. Yu. Klinicheskayatipologiyapsikhopatologicheskikhrasstroistv u potrebiteleisinteticheskikhkannabinoidov (spaisov) // Sibirskiivestnikpsikhiatriiinarkologii. -2015.-№ 4 (89). - s. 18-23. (In Russ.).
[6]
Bondar' I. V, Nadezhdin A. V., Vyazovichenko Yu. E., Simonov D. V., Vishnyakov D. A. Ob aktual'nosti problemy kuritel'nykh smesei (spaisov) na sovremennom etape // sbornik materialov Vserossiiskoi nauchno-prakticheskoi konferentsii «Protivodeistvie nezakonnomu oborotu narkoticheskikh sredstv, psikhotropnykh veshchestv, ikh analogov i prekursorov v sovremennoi rossii: ugolovno-pravovoi i kriminologicheskii aspekty» / pod obshch. red. I. I. Batyrshina. – M.: FKU NITs FSKN Rossii, 2015. –s. 27-32. (In Russ.).
[7]
Gordeev A. Yu. K voprosu o protivodeistvii nezakonnomu oborotu novykh vidov psikhoaktivnykh veshchestv // sbornik materialov Vserossiiskoi nauchno-prakticheskoi konferentsii «Protivodeistvie nezakonnomu oborotu narkoticheskikh sredstv, psikhotropnykh veshchestv, ikh analogov i prekursorov v sovremennoi rossii: ugolovno-pravovoi i kriminologicheskii aspekty»/ pod obshch. red. I. I. Batyrshina. – M.: FKU NITs FSKN Rossii, 2015. –s. 63-66.
[8]
Vearrier, D. and Osterhoudt, K. (2010). A Teenager With Agitation. Pediatric Emergency Care, 26 (6), pp. 462-465. doi: 10.1097/PEC.0b013e3181e4f416.
[9]
Rodgman, C., Kinzie, E. and Leimbach, E. (2011). Bad Mojo: use of the new marijuana substitute leads to more and more ED visits for acute psychosis. The American Journal of Emergency Medicine, 29 (2), p. 232. doi: 10.1016/j.ajem.2010.07.020.
[10]
Hurst, D., Loeffler, G. and McLay, R. (2011). Psychosis Associated With Synthetic Cannabinoid Agonists: A Case Series. American Journal of Psychiatry, 168 (10), pp. 1119-1119. doi: 10.1176/appi.ajp.2011.11010176.
[11]
Benford, D. and Caplan, J. (2011). Psychiatric Sequelae of Spice, K2, and Synthetic Cannabinoid Receptor Agonists. Psychosomatics, 52 (3), p. 295. doi:10.1016/j.psym.2011.01.004.
[12]
Van Der Veer, N. and Friday, J. (2011). Persistent psychosis following the use of Spice. SchizophreniaResearch, 130 (1-3), pp. 285-286. doi:10.1016/j.schres.2011.04.022.
[13]
Bebarta, V., Ramirez, S. and Varney, S. (2012). Spice: A New «Legal» Herbal Mixture Abused by Young Active Duty Military Personnel. Substance Abuse, 33 (2), pp. 191-194. doi: 10.1080/08897077.2011.637610.
[14]
Hermanns-Clausen, M., Kneisel, S., Hutter, M., Szabo, B. and Auwärter, V. (2013). Acute intoxication by synthetic cannabinoids - Four case reports. Drug Testing and Analysis, 5 (9-10), pp. 790-794. doi: 10.1002/dta.1483.
[15]
Hermanns-Clausen, M., Kneisel, S., Szabo, B. and Auwärter, V. (2012). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, 108 (3), pp. 534-544. doi: 10.1111/j.1360-0443.2012.04078.x.
[16]
Peglow, S., Buchner, J. and Briscoe, G. (2012). Synthetic Cannabinoid Induced Psychosis in a Previously Nonpsychotic Patient. The American Journal on Addictions, 21 (3), pp. 287-288. doi: 10.1111/j.1521-391.2012.00222.x.
[17]
Schwartz, M., Trecki, J., Edison, L., Steck, A., Arnold, J. and Gerona, R. (2015). A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA. The Journal of Emergency Medicine, 48 (5), pp. 573-580. doi: 10.1016/j.jemermed.2014.12.038.
[18]
Fattore, L. (2016). Synthetic Cannabinoids—Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis. Biological Psychiatry, 79 (7), pp. 539-548. http://dx.doi.org/10.1016/j.biopsych.2016.02.001.
Browse journals by subject